"Validation of a Novel Smartphone-Based Point-of-Care Semen Analysis System to Evaluate Male Reproductive Potential: A Concordance Study with Computer-Assisted Sperm Analysis," officially published in the prestigious, peer-reviewed journal Diagnostics (MDPI).
We are officially announcing a major clinical milestone that establishes a new technological benchmark in the global male reproductive healthcare market. Our comprehensive clinical concordance study has been formally published in the prestigious, peer-reviewed SCI-level international medical journal, Diagnostics (MDPI).
Conducted in rigorous collaboration with the world-class CHA Fertility Center and CHA University, this publication delivers definitive, institutional-grade validation for our smartphone-based POCT semen analysis platform, HAGOBOGO PRO.
Key Research Findings & Data Validation
The most critical and definitive conclusion of this peer-reviewed paper is that HAGOBOGO PRO demonstrated high clinical concordance and no statistically significant difference ($p > 0.05$) when compared directly against high-end, institutional Computer-Assisted Sperm Analysis (CASA) equipment costing tens of thousands of dollars.
Study Methodology: The study analyzed 520 video microscopy clips strictly under the WHO 2021 (6th edition) guidelines.
Laboratory-Grade Accuracy: Proved high precision with a concentration correlation of $\rho = 0.943$.
High Reproducibility: Demonstrated an intra-assay CV under 6%.
Bridging the Gap in Male Fertility Healthcare
With male factor dynamics contributing to approximately 40–50% of global infertility cases, many men still hesitate to visit fertility clinics early due to psychological and logistical barriers.
HAGOBOGO PRO is designed not to replace professional laboratory evaluations, but to act as a vital bridge to them.
By offering an accurate and private preliminary screening tool, our system empowers men to take the first step at home, actively encouraging those in need to seek timely professional medical care.
Strategic Partnership & Distribution Opportunities
This SCI-level validation provides you with the ultimate scientific credibility to build strong collaborative partnerships with local fertility clinics and healthcare providers. Instead of competing with medical institutions, you are offering them a powerful solution that increases early patient screening rates and drives qualified referrals straight to specialized clinics.
The science has spoken, and the product is definitively proven. Given the immense global demand and the undeniable strength of this clinical backing, we are currently prioritizing discussions for exclusive national distribution rights.
Next Steps & Contact Information
The complete paper is fully open-access for your review. We have also attached the official data summary to this email.
If you would like to know more about this advanced system, or if you need a detailed introduction to how we can support your business, please feel free to reach out to us at any time. We are always here to help and answer your questions.
Sincerely,
INTIN Inc.
